健择联合卡铂治疗晚期肺癌被引量：2

Combination chemotherapy with gemcitabine plus carboplatin in advanced lung cancer

下载PDF

导出

摘要目的　研究健择联合卡铂治疗晚期肺癌的疗效及毒性反应。方法　经病理组织学或细胞学证实的 5 8例的晚期肺癌患者给予健择 10 0 0mg m2 静脉滴注 ,第 1、 8天 ;卡铂第 1天以AUC=5计算所得的剂量 ,静脉滴注 ,2 1天为 1周期。结果　可评价疗效 5 8例 ,CR 1例 ,PR 2 9例 ,SD 2 1例 ,PD 7例 ,RR为 5 1 7%。毒副作用主要为白细胞及血小板减少 ,但均可耐受 ,胃肠道反应及肾毒性轻。结论　健择联合卡铂治疗晚期肺癌疗效确切 ,毒副作用可以耐受。 Objective To evaluate the effect and adverse effect of gemcitabine combined with carboplatin therapy in advanced lung cancer.Methods 58 advanced patients with lung cancer diagnosed by pathology or cytology were enrolled.All patients received gemcitabine 1000 mg/m 2 on the d 1,8,and carboplatin AUC=5 in the first day.Three weeks repeated.Results In the 58 appreciable patients,there were 1 completeresponses,29 partial responses,21 stable disease,7progressive disease,the response rate being 51.7%.The major side reaction was thromasthenia and leucopeniano,but the toxicity was acceptable.Other toxicities were mild and tolerable.Conclusion Combination chemo-therapy with gemcitabine plus carboplatin has a high response with acceptable toxicity in advanced lung cancer.

作者李静刘基巍李丽邓晓琴

机构地区大连医科大学附属第一医院肿瘤科

出处《癌症进展》 2004年第5期380-383,共4页 Oncology Progress

关键词健择卡铂晚期肺癌 gemcitabine carboplatin aduanced lung cancer

分类号 R734.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1[1]Barton BM. Gemcitabine: A pharmacologic and clinical overview. Cancer, 1999, 22 (2) :176
2[2]Manegold C, Bergmann B, Chemaissani A, et al. Singleagent gemcitabine versus cisplatin- etoposide: Early results of a randomized phase Ⅱ study in locally advanced or metastatic non -small cell lung cancer. AnnOncol, 1997, 8 (6) :525
3[3]Peng RP, Chen YM, Ming- Liu J, et al. Gemcitabine versus the combination of cispatin and etoposide in patients with inoperable non- small cell lung cancer in a phase Ⅱ randomized study.J Clin Oncol, 1997, 15 (5) :2097
4[4]Non- small Cell Lung Cancer Collabortive Group. Chemotherapy in non- small- cell lung cancer: A meta- analysis using updated date on individual patients from 52 randomized clinical trials.BMJ, 1995, 311 (7010) :899
5[5]Johnson DH. Gemcitabine for the treatment of non- small - cell lung cancer. Oncology (Huntington), 2001, 15 (Suppl 7) :7
6于世英.吉西他滨用于非小细胞肺癌治疗的研究进展[J].中国癌症杂志,2001,11(4):367-370. 被引量：46

二级参考文献20

1[1]Manegold C, Zatloukal P, Krejcy K, et al. Gemcitabine in non-small-cell lung cancer[J]. Invest New Drugs,2000,18(1):29-42.
2[2]Merimsky O, Wigler N, Greif Y, et al. Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small-cell lung cancer: a phase Ⅱ study[J]. Anticancer Drugs,2000,11(2):117-121.
3[3]Sandler AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2000,18(1):122-130.
4[4]Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,1999,17(1):12-18.
5[5]Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase Ⅲ study of the Italian Lung Cancer Project[J]. J Clin Oncol1999,17(11):3522-3530.
6[6]Schiller J, Harrington D, Sandler A, et al. A randomized phase III trial of fourchemotherapy regimens in advanced non-samll cell lung cancer (NSCLC)[J]. Am Soc Clin Oncol,2000,19:1-1.
7[7]Kroep JR, Peters GJ, van Moorsel CJA, et al. Gemcitabine-cisplatin: A schedule finding study[J]. Ann Oncol,1999,10(12):1503-1510.
8[8]Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer[J]. J Clin Oncol,1999,17(7):2190-2197.
9[9]Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung Cancer[J]. Ann Oncol1999,10(9):1043-1049.
10[10]Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase Ⅱ trial[J]. J Clin Oncol,1999,17(3):914-920.